Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Mallinckrodt

Last Updated: September 25, 2022

LAMICTAL CD Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Lamictal Cd patents expire, and what generic alternatives are available?

Lamictal Cd is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in LAMICTAL CD is lamotrigine. There are thirty-two drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lamictal Cd

A generic version of LAMICTAL CD was approved as lamotrigine by DR REDDYS LABS LTD on January 22nd, 2009.

  Try it Free

Drug patent expirations by year for LAMICTAL CD
Recent Clinical Trials for LAMICTAL CD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Phase 2
Brown UniversityPhase 2
Dent Family FoundationPhase 2

See all LAMICTAL CD clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for LAMICTAL CD

US Patents and Regulatory Information for LAMICTAL CD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-004 Sep 8, 2000 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-003 Aug 24, 1998 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-001 Aug 24, 1998 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-002 Aug 24, 1998 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LAMICTAL CD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-004 Sep 8, 2000 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-002 Aug 24, 1998 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-001 Aug 24, 1998 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-001 Aug 24, 1998 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-003 Aug 24, 1998 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-004 Sep 8, 2000 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Llc LAMICTAL CD lamotrigine TABLET, FOR SUSPENSION;ORAL 020764-003 Aug 24, 1998 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LAMICTAL CD

See the table below for patents covering LAMICTAL CD around the world.

Country Patent Number Title Estimated Expiration
Finland 67844 See Plans and Pricing
Zimbabwe 12980 SUBSTITUTED AROMATIC COMPOUNDS See Plans and Pricing
Canada 1133938 COMPOSES AROMATIQUES SUBSTITUES (SUBSTITUTED AROMATIC COMPOUNDS) See Plans and Pricing
Japan H0144706 See Plans and Pricing
Australia 530999 See Plans and Pricing
Ireland 49823 1,2,4-TRIAZINE DERIVATIVES,PROCESS FOR PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM See Plans and Pricing
Finland 73203 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKinsey
AstraZeneca
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.